News

Dr. Philip M Arlen to present at DDIP 2025, March 3-4, 2025, San Diego, CA

Strattmont Group2025-05-14T12:53:44-04:00

Precision Biologics, Inc. CEO, Philip M Arlen, MD, will participate on an interactive panel (Day...

Precision Biologics to Announce Development of New Monoclonal Antibody (mAb) PB-223 at SITC, Houston, TX, November 7-8, 2024

Strattmont Group2024-11-06T14:00:48-05:00

Precision Biologics will present affinity maturation and characterization of a novel core 2 O-glycan epitope...

Precision Biologics, Inc. to present recent data on the development of new monoclonal antibody (mAb) PB-223 at SITC 2024

Strattmont Group2024-11-04T11:13:35-05:00

Precision Biologics, Inc. will present novel data about affinity maturation and characterization of a novel...

Dr. Philip M. Arlen, CEO, to give opening keynote for Immuno US 2024 Conference, San Diego, CA, October 28th, 2024

Strattmont Group2024-10-22T14:37:59-04:00

DOWNLOAD 1

Precision Biologics, Inc. announces new US Patent filing on optimized antibody PB-233

Strattmont Group2024-09-24T12:26:59-04:00

Precision Biologics announces the filing of a new patent for our second asset, PB-233. This...

Precision Biologics announces publication of a new review article in Expert Review of Vaccines, September 1st, 2024.

Strattmont Group2024-09-09T11:34:10-04:00

Precision Biologics announces that a review, entitled "Generation of the therapeutic monoclonal antibody NEO-201, derived...

Precision Biologics Awarded New Patent on NEO-201 for Treg Depletion

Strattmont Group2024-07-22T12:26:35-04:00

Precision Biologics awarded new US Patent on its lead monoclonal antibody NEO-201 for regulatory T-cell...

Precision Biologics to present at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting

Strattmont Group2024-05-31T11:23:21-04:00

Precision Biologics presents new data from ongoing clinical trial combining NEO-201 with pembrolizumab at the...